[Twice daily irradiation of nasopharyngeal lymphosarcomas and cancer].
The authors present the preliminary results of double daily irradiation with a 4-hour interval of patients with rhinopharyngeal cancer (30 persons) and lymphosarcoma (18). This irradiation variant was well tolerated; all the patients received radiotherapy in accordance with the plan of irradiating tumors with mean focal doses of 70-76 Gy for rhinopharyngeal cancer and 40-50 Gy for lymphosarcoma. Complete tumor regression by the end of radiotherapy was achieved in 75%, partial in 25% of patients with rhinopharyngeal cancer. In lymphosarcoma, these figures were 80 and 20%, respectively. No late injuries of the normal tissues after 6-36 months were noted in patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005720:Gamma Rays / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D013997:Time Factors
Dvukratnoe ezhednevnoe obluchenie limfosarkom i raka nosoglotki.